Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by word99on Dec 23, 2019 3:51pm
381 Views
Post# 30485233

Acasti

Acasti

Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today

ACST is seeing heavy trading today

Acasti Pharma (NASDAQ:ACST) is having trouble on Monday as ACST stock has fallen a great deal.

Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today
Source: Shutterstock

No new Acasti Pharma news may lead some investors in ACST stock to wonder why it’s trading lower today. There are no official announcements from the company and analysts have been quiet about the stock of late.

It looks like the problem for ACST stock has less to do with news and more to do with trading. As of Monday afternoon, there have been a total of 13,510,517 shares changing hands. That’s incredibly high compared to the typical daily average of 2,054,323 shares.

It’s likely that this massive influx of trading resulted in ACST stock taking a dive, which explains why there’s no specific Acasti Pharma news hitting the stock. A massive amount of trading can hurt a stock in the short-term, but oftentimes it will recover. That’s not the case this time around.

So why exactly is ACST stock still down so low today? The trading of the stock has come to a stop. The last update for the stock’s price comes from 1:30 p.m. Eastern Time. It’s possible that this freeze on trading is keeping the stock from recovering completely. Looking at its price chart, investors can see that the stock was beginning to make a comeback before the freeze put an end to it.

ACST stock was down 24.04% as of Monday afternoon. It’s currently up 218.89% since the start of the year.


Bullboard Posts